Magenta Therapeutics (NASDAQ:MGTA) and closely-held Dianthus Therapeutics entered into a definitive merger agreement to combine the companies in an all-stock transaction that is expected to close in the third quarter of...
Search results for - MGTA
Magenta Therapeutics reports initial Phase 2 data for stem cell therapy
Magenta Therapeutics (NASDAQ:MGTA) reported preliminary data from its Phase 2 trial testing MGTA-456, a hematopoietic stem cell (HSC) therapy, in patients with inherited metabolic disorders. The Phase 2 study is...
